Lumibird (HAM:QTL) PE Ratio without NRI: 32.98 (As of Jun. 26, 2026) — 12% Above Median


HAM:QTL Lumibird HAM:QTL
65 GF Score
Price €23.25
GF Value €16.31
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lumibird PE Ratio without NRI?

Lumibird HAM:QTL -3.93% 65 PE Ratio without NRI is 32.98 as of Jun. 26, 2026, which is 12% above its 10-year median of 29.46. GuruFocus rates HAM:QTL with a GF Score™ of 65/100 and a GF Value™ of €16.31 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, Lumibird ranks worse than 60.2% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-26), Lumibird's share price is €23.25. Lumibird's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.71. Therefore, Lumibird's PE Ratio without NRI for today is 32.98.

During the past 13 years, Lumibird's highest PE Ratio without NRI was 119.68. The lowest was 11.49. And the median was 29.46.

Lumibird's EPS without NRI for the six months ended in Dec. 2025 was €0.47. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was €0.71.

As of today (2026-06-26), Lumibird's share price is €23.25. Lumibird's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.64. Therefore, Lumibird's PE Ratio (TTM) for today is 36.33.

During the past years, Lumibird's highest PE Ratio (TTM) was 150.14. The lowest was 11.98. And the median was 31.49.

Lumibird's EPS (Diluted) for the six months ended in Dec. 2025 was €0.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.64.

Lumibird's EPS (Basic) for the six months ended in Dec. 2025 was €0.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.64.


Lumibird  (HAM:QTL) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Lumibird PE Ratio without NRI Related Terms


Lumibird PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Lumibird's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumibird PE Ratio without NRI Chart

Lumibird Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.64 34.72 20.57 23.58 30.07

Lumibird Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.57 At Loss 23.58 At Loss 30.07

HAM:QTL vs TMO, DHR, IDXX: PE Ratio without NRI Comparison

For the Diagnostics & Research subindustry, Lumibird's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumibird PE Ratio without NRI vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lumibird's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Lumibird's PE Ratio without NRI falls into.


HAM:QTL
65GF Score
Lumibird HAM:QTL
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lumibird PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Lumibird's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=23.25/0.705
=32.98

Lumibird's Share Price of today is €23.25.
For company reported semi-annually, Lumibird's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.71.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 32.98 mean?
Lumibird (HAM:QTL) has a PE Ratio without NRI of 32.98 as of Jun. 26, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Lumibird and its competitors. This is 12% above median its historical median of 29.46. Over the past decade, Lumibird's PE Ratio without NRI has ranged from 11.49 to 119.68. According to the industry distribution chart, Lumibird ranks #59 out of 98 companies in the Medical Diagnostics & Research industry, placing it in the top 60.2%.
Is Lumibird's PE Ratio without NRI too high?
Lumibird's current PE Ratio without NRI of 32.98 is 12% above median its 10-year median of 29.46. Over the past 10 years, this metric has ranged from a low of 11.49 to a high of 119.68. The Medical Diagnostics & Research industry median PE Ratio without NRI is 28.06. Lumibird's value of 32.98 is 17.5% above this industry median. Based on the distribution chart, Lumibird ranks #59 out of 98 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Lumibird has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumibird's PE Ratio without NRI compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumibird ranks #59 out of 98 companies for PE Ratio without NRI. This places Lumibird in the lower half of its industry. The industry median PE Ratio without NRI is 28.06. Lumibird's value of 32.98 is 17.5% above this benchmark. Historically, Lumibird's own PE Ratio without NRI has ranged from 11.49 to 119.68 over the past decade. While the company's 10-year median is 29.46 vs. the industry median of 28.06, Lumibird has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Diagnostics & Research company?
The median PE Ratio without NRI among Medical Diagnostics & Research companies is 28.06, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumibird's current PE Ratio without NRI of 32.98 is 17.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Lumibird and its competitors. For the Medical Diagnostics & Research industry, the median PE Ratio without NRI is 28.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumibird's current PE Ratio without NRI is 32.98, which is 12% above median its own 10-year median of 29.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumibird stock overvalued right now?
Based on GuruFocus' analysis, Lumibird (HAM:QTL) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.31, compared to a current price of €23.25 — trading 42.6% above its estimated fair value. The current PE Ratio without NRI is 32.98, which is 12% above median its 10-year median of 29.46 and 17.5% above the Medical Diagnostics & Research industry median of 28.06. Lumibird's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Lumibird (HAM:QTL), the current PE Ratio without NRI is 32.98 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumibird (HAM:QTL) Overvalued in 2026?

Based on GuruFocus' analysis, Lumibird stock appears to be overvalued. The current stock price of €23.25 is trading 42.6% above its estimated GF Value™ of €16.31. GuruFocus considers Lumibird to be Significantly Overvalued.

Key valuation signals for HAM:QTL:

  • PE Ratio without NRI: 32.98 (12% above median its 10-year median of 29.46)
  • GF Value™: €16.31 vs. price of €23.25 (42.6% above fair value)
  • GF Score™: 65/100 with 5 warning signs
  • Industry Position: 17.5% above the Medical Diagnostics & Research median (#59 of 98)

No single metric tells the full story. See the HAM:QTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lumibird Business Description

Address 2 rue du Paul Sabatier, Lannion, FRA, 22300
Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications.
65GF Score

Get the complete analysis for HAM:QTL

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€23.25
Price
€16.31
GF Value